AU2011276365B2 - Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA - Google Patents

Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA Download PDF

Info

Publication number
AU2011276365B2
AU2011276365B2 AU2011276365A AU2011276365A AU2011276365B2 AU 2011276365 B2 AU2011276365 B2 AU 2011276365B2 AU 2011276365 A AU2011276365 A AU 2011276365A AU 2011276365 A AU2011276365 A AU 2011276365A AU 2011276365 B2 AU2011276365 B2 AU 2011276365B2
Authority
AU
Australia
Prior art keywords
seq
strand
dsrna
target
catenin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011276365A
Other languages
English (en)
Other versions
AU2011276365A1 (en
Inventor
Bob Dale Brown
Henryk T. Dudek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dicerna Pharmaceuticals Inc
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of AU2011276365A1 publication Critical patent/AU2011276365A1/en
Application granted granted Critical
Publication of AU2011276365B2 publication Critical patent/AU2011276365B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011276365A 2010-07-06 2011-07-01 Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA Ceased AU2011276365B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36177610P 2010-07-06 2010-07-06
US61/361,776 2010-07-06
PCT/US2011/042820 WO2012006243A2 (en) 2010-07-06 2011-07-01 Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna

Publications (2)

Publication Number Publication Date
AU2011276365A1 AU2011276365A1 (en) 2013-01-10
AU2011276365B2 true AU2011276365B2 (en) 2017-05-11

Family

ID=45441761

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011276365A Ceased AU2011276365B2 (en) 2010-07-06 2011-07-01 Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA

Country Status (9)

Country Link
US (5) US8815825B2 (https=)
EP (4) EP3037538B1 (https=)
JP (1) JP5976643B2 (https=)
AU (1) AU2011276365B2 (https=)
CA (2) CA2804214C (https=)
DK (3) DK3037538T3 (https=)
ES (3) ES2635388T3 (https=)
PT (1) PT3587579T (https=)
WO (1) WO2012006243A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2802658A2 (en) * 2012-01-09 2014-11-19 Novartis AG Rnai agents to treat beta-catenin related diseases
US10753938B2 (en) * 2015-03-04 2020-08-25 The University Of Chicago Beta-catenin inhibitors in cancer immunotherapy
US10821112B2 (en) 2016-03-16 2020-11-03 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
WO2017173297A1 (en) * 2016-04-01 2017-10-05 Avidity Biosciences Llc Beta-catenin nucleic acids and uses thereof
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
US10407681B2 (en) * 2017-03-28 2019-09-10 The United States Of America, As Represented By The Secretary Of Agriculture Plant-mediated silencing of a fatty acid and retinoid binding protein in Pratylenchus penetrans
CA3057679A1 (en) * 2017-03-28 2018-10-04 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin expression to potentiate immunotherapy
WO2019079472A1 (en) * 2017-10-18 2019-04-25 Dicerna Pharmaceuticals, Inc. BETA-CATENIN NUCLEIC ACID INHIBITOR MOLECULE
WO2019100039A1 (en) * 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
US11813280B2 (en) 2018-01-05 2023-11-14 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
EP3740248A4 (en) * 2018-03-02 2022-01-26 Dicerna Pharmaceuticals, Inc. Methods and compositions for treating bile duct paucity-associated conditions
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
AU2022316139A1 (en) * 2021-07-23 2024-01-18 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113351A1 (en) * 2004-05-11 2008-05-15 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
WO2008109460A2 (en) * 2007-03-02 2008-09-12 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting ctnnb1 gene expression and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
ES2061416T3 (es) 1990-10-12 1997-03-01 Max Planck Gesellschaft Ribozimas modificadas.
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US20030064384A1 (en) * 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
US20060019917A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
CA2521464C (en) 2003-04-09 2013-02-05 Alnylam Pharmaceuticals, Inc. Irna conjugates
JP4912873B2 (ja) * 2003-04-09 2012-04-11 アルナイラム ファーマシューティカルズ， インコーポレイテッド ｉＲＮＡ複合体
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
US20090012018A1 (en) * 2004-09-13 2009-01-08 Matthias Hebrok Inhibition of pancretic cancer cell growth
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
WO2007031091A2 (en) * 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
DK2152879T3 (da) * 2007-05-01 2013-02-18 Santaris Pharma As RNA antagonistforbindelser til modulering af beta-catenin
US20100239546A1 (en) * 2007-06-15 2010-09-23 Beth Israel Deaconess Medical Center Bacterial mediated tnf alpha gene silencing
TWI455944B (zh) * 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd 雙股多核苷酸
JP2012005734A (ja) 2010-06-28 2012-01-12 Panasonic Corp 電気掃除機用吸込具及びそれを備えた電気掃除機
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113351A1 (en) * 2004-05-11 2008-05-15 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
WO2008109460A2 (en) * 2007-03-02 2008-09-12 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting ctnnb1 gene expression and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sun, X. et al., Nature Biotechnology, 2008, vol. 26, no. 12, pages 1379-1382. *

Also Published As

Publication number Publication date
CA2804214C (en) 2022-04-12
EP3587579B1 (en) 2021-03-03
WO2012006243A2 (en) 2012-01-12
EP3037538B1 (en) 2019-05-01
JP5976643B2 (ja) 2016-08-24
EP3854874A1 (en) 2021-07-28
CA2804214A1 (en) 2012-01-12
ES2635388T3 (es) 2017-10-03
DK3587579T3 (da) 2021-04-26
US10072263B2 (en) 2018-09-11
US20190002879A1 (en) 2019-01-03
DK3037538T3 (da) 2019-06-24
EP3587579A1 (en) 2020-01-01
CA3146952A1 (en) 2012-01-12
ES2734743T3 (es) 2019-12-11
EP3037538A1 (en) 2016-06-29
DK2591105T3 (en) 2017-07-31
ES2873893T3 (es) 2021-11-04
EP2591105A2 (en) 2013-05-15
EP2591105B1 (en) 2017-05-31
US20160186176A1 (en) 2016-06-30
US9428752B2 (en) 2016-08-30
US20130109740A1 (en) 2013-05-02
AU2011276365A1 (en) 2013-01-10
JP2013534425A (ja) 2013-09-05
US8815825B2 (en) 2014-08-26
EP2591105A4 (en) 2014-09-10
PT3587579T (pt) 2021-05-24
US20160053263A1 (en) 2016-02-25
US9243244B2 (en) 2016-01-26
WO2012006243A3 (en) 2012-06-14
HK1227054A1 (en) 2017-10-13
US10612023B2 (en) 2020-04-07
US20140288292A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
US10612023B2 (en) Methods and compositions for the specific inhibition of β-catenin by double-stranded RNA
AU2010232410B2 (en) Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
EP2756845A1 (en) Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
AU2011276363A1 (en) Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNA
AU2013315543A1 (en) Methods and compostions for the specific inhibition of MYC by double-stranded RNA
WO2010115202A2 (en) Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
WO2015100436A1 (en) Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
WO2013138668A1 (en) Methods and compositions for the specific inhibition of mcl1 by double-stranded rna
WO2014093746A2 (en) Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
US10011834B2 (en) Methods and compositions for the specific inhibition of HIF-1α by double-stranded RNA
HK40059743A (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
HK1227054B (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired